Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
A Phase IIA Open-Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels.
Not Open (Closed)
Chemotherapy: Systemic, Immunotherapy
Defintions of terms and FAQ about clinical trials.
Heinz Josef Lenz, M.D.
Other Trial Staff:
Ramona Lujan, R.N., Raluca Agafitei, Coordinator, Taison Tran, D.M., Khatchik Karakozian, D.M.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.